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Abstract 
Friedreich's ataxia is a neurodegenerative disorder associated with cardiomyopathy 
and diabetes. Effective therapies for Friedreich’s ataxia are an urgent unmet need; 
there are currently no options to prevent or treat this orphan disease. Friedreich’s 
ataxia is caused by reduced expression of the mitochondrial protein frataxin. We have 
previously demonstrated that pancreatic β-cell dysfunction and death cause diabetes 
in Friedreich’s ataxia. This is secondary to mitochondrial dysfunction and apoptosis 
but the underlying molecular mechanisms are not known. Here we show that β-cell 
demise in frataxin deficiency is the consequence of oxidative stress-mediated 
activation of the intrinsic pathway of apoptosis. The pro-apoptotic Bcl-2 family 
members Bad, DP5 and Bim are the key mediators of frataxin deficiency-induced β-
cell death. Importantly, the intrinsic pathway of apoptosis is also activated in 
Friedreich’s ataxia patients’ induced pluripotent stem cell-derived neurons. 
Interestingly, cAMP induction normalizes mitochondrial oxidative status and fully 
prevents activation of the intrinsic pathway of apoptosis in frataxin-deficient β-cells 
and neurons. This preclinical study suggests that incretin analogs hold potential to 
prevent/delay both diabetes and neurodegeneration in Friedreich’s ataxia. 
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Introduction 
Friedreich’s ataxia (FRDA) is an autosomal recessive neurodegenerative disease 
caused by a GAA trinucleotide repeat expansion in the first intron of the FXN gene, 
encoding the mitochondrial protein frataxin (1). This expansion interferes with 
frataxin transcription by heterochromatin silencing (1, 2). FRDA patients have 5-35% 
of normal frataxin levels, and this is the cause of the clinical and pathophysiological 
features of the disease (3). FRDA is characterized by progressive gait ataxia, muscle 
weakness, dysarthria, and sensory loss (4). In addition to the neurological phenotype, 
FRDA patients have high prevalence of hypertrophic cardiomyopathy (4, 5), glucose 
intolerance and diabetes (6, 7). 
The main neuropathological features are loss of large proprioceptive primary sensory 
neurons in the dorsal root ganglia, atrophy of the posterior columns and the 
spinocerebellar tracts in the spinal cord, severe neuronal loss in the dentate nucleus in 
the cerebellum, and distal axonal loss in the pyramidal tracts, with variable 
involvement of visual and auditory pathways (8, 9). We have recently demonstrated 
that pancreatic β-cell dysfunction and loss are central for diabetes development in 
FRDA patients (10, 11). 
Frataxin is a component of the multiprotein complex that assembles iron-sulfur (Fe-S) 
clusters in mitochondria, where it allosterically activates the sulfur donor enzyme 
NSF1 and modulates iron entry in the complex. Frataxin deficiency results in 
decreased Fe-S biogenesis and loss of activity of Fe-S enzymes, including several 
subunits of complexes I, II and III of the respiratory chain, whose impairment leads to 
energy deficit and enhanced production of reactive oxygen species (ROS). Frataxin-
deficient cells accumulate iron, mostly in mitochondria, likely as a consequence of a 
homeostatic mechanism trying to restore Fe-S cluster synthesis. Excess mitochondrial 
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iron reacts with ROS and generates toxic radicals causing oxidative damage (12-15). 
Cells from FRDA patients and cells rendered frataxin-deficient by RNA interference 
show mitochondrial dysfunction and enhanced susceptibility to ROS (16). Frataxin 
silencing in neuron-like cells, obtained by differentiating neuroblastoma cells, 
induced accumulation of ROS and apoptosis (17). We have shown that frataxin 
silencing in pancreatic β-cells induces mitochondrial dysfunction and apoptosis under 
basal condition and following metabolic or endoplasmic reticulum (ER) stress (10). 
Interestingly, cAMP induction by incretin analogs was protective in frataxin-deficient 
β-cells (10, 11).  
In eukaryotic cells, apoptosis can be executed via two molecular pathways: the 
extrinsic and the intrinsic pathway of apoptosis (18). The latter, also called 
mitochondrial pathway of apoptosis, is activated in response to ER stress, DNA 
damage, and mitochondrial dysfunction. The propensity of cells to undergo apoptosis, 
known as the apostat, is determined by the balance and interactions between pro- and 
anti-apoptotic proteins of the Bcl-2 family (19-21). The pro-apoptotic Bcl-2 proteins 
are divided into BH3-only sensitizers and activators. Sensitizers are activated 
transcriptionally (e.g. DP5, Bik and Noxa) or by dephosphorylation (e.g. Bad) and 
directly bind pro-survival family members (e.g. Bcl-XL, Bcl-2 and Bcl-2A1) causing 
the release of the activators (e.g. Bim, Puma and tBid). When freed in the cytoplasm 
the activators bind and activate pro-death binding partners such as Bax and Bak 
through a conformational change, leading to their translocation to the mitochondria, 
outer mitochondrial membrane permeabilization, cytochrome c release, activation of 
the initiator caspase-9 and the effector caspase-3 and execution of cell death. The 
usage of Bcl-2 proteins following different pro-apoptotic stimuli is context-dependent 
(19). 
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The apoptosis pathway and mediators activated by frataxin deficiency in FRDA are 
unknown. The aim of this study was to elucidate the molecular mechanisms of 
apoptosis in cell models relevant to this severe disease. Since FRDA is caused by 
partial frataxin deficiency (absolute deficiency being lethal), RNA interference 
technology allows for mechanistic studies in in vitro cell models (11). More recently, 
induced pluripotent stem cells (iPSCs), derived from FRDA patient fibroblasts, have 
been differentiated into neurons and cardiomyocytes (22-25). The FRDA patients’ 
iPSC-derived neurons recapitulate the genetic basis of the disease, the decreased 
frataxin expression and the mitochondrial defects (25). Using these two models we 
presently demonstrate that cell death in FRDA is mediated by enhanced mitochondrial 
oxidative stress and activation of the intrinsic pathway of apoptosis. The pro-
apoptotic Bcl-2 proteins Bad, DP5 and Bim are the key mediators of cell death in 
frataxin deficiency. Forskolin reduces mitochondrial oxidative stress and prevents 
activation of the intrinsic pathway of apoptosis through selective modulation of pro-
apoptotic Bcl-2 proteins. Thus, cAMP induction has therapeutic potential to prevent 
the loss of β-cells and neurons in FRDA 
 
Results 
Frataxin deficiency in β-cells enhances mitochondrial hydrogen peroxide 
and hydroxyl radical formation.  
We have previously demonstrated that frataxin deficiency induces mitochondrial 
dysfunction and sensitizes β-cells to free fatty acid (FFA)- and ER stress-induced 
apoptosis (10). In other cell types frataxin deficiency enhances oxidative stress (1, 3, 
26, 27). To determine if this is also a characteristic of frataxin-deficient β-cells, we 
knocked down frataxin in clonal rat INS-1E β-cells (Fig. 1) using one of our 
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previously validated siRNAs (10). Frataxin silencing induced β-cell death (Fig. 1A-C) 
and enhanced the expression of mitochondrial superoxide dismutase (SOD2, Fig. 1D). 
This enzyme catalyzes the dismutation of superoxide radicals to H2O2 and oxygen. 
We therefore examined whether mitochondrial H2O2 production is increased, using 
the specific fluorescent H2O2 sensor HyPer. Oxidation of HyPer, selectively targeted 
to the mitochondria (HyPerMito, Fig. 1E), was significantly increased in frataxin-
deficient β-cells in control condition and after treatment with the FFA oleate or the 
ER stressor brefeldin (Fig. 1E). In contrast, cytosolic H2O2 formation, monitored by 
HyPerCyto oxidation, was not modified by frataxin deficiency (Fig. 1F). H2O2 is 
converted into the highly reactive hydroxyl radical (OH) in the presence of ferrous 
iron via the Fenton reaction (28). Using the fluorescent dye HPF, enhanced OH 
formation was detected in frataxin-deficient β-cells (Fig.1G). We also examined 
whether frataxin silencing modifies the thiol/disulfide mitochondrial redox 
equilibrium, by targeting the redox sensitive biosensor roGFP to the mitochondria 
(mt-roGFP1). This biosensor, which is much less pH-sensitive than HyPerMito (29), 
reports the mitochondrial glutathione (GSH) redox state, reflecting the cellular 
capacity to reduce oxidized protein-thiols via the thiol based redox couple 
GSH/GSSG (30). In line with our observation of enhanced mitochondrial ROS 
production in frataxin deficiency, frataxin silencing increased mitochondrial GSH 
oxidation (Fig. 1H). In summary, frataxin deficiency induces mitochondrial oxidative 
stress and apoptosis in β-cells. 
 
Oxidative stress contributes to apoptosis in frataxin-deficient β-cells.  
We next used chemical and genetic approaches to examine whether increased 
oxidative stress mediates β-cell death. Apoptosis induced by frataxin silencing was 
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partially prevented by the cell-permeable SOD/catalase mimetic MnTMPyP (31-33) 
and the superoxide anion scavenger Tiron (34) in control condition and after oleate 
(Fig. 2A, F) or brefeldin treatment (Fig. 2D). These results were confirmed by 
Western blot for cleaved caspase-3 (Fig. 2Β-C). MnTMPyP also protected frataxin-
deficient rat islet cells from oleate-induced apoptosis (Fig. 2E and Supplementary 
Material, Fig. S1). Mitochondrial overexpression of the H2O2-inactivating enzyme 
catalase increased catalase activity by around 20-fold (6±2 units in control cells vs 
135±21 units in mitochondrial calatase overexpressing cells, n=6-11, p<0.001 by 
paired t test). Mitochondrial catalase overexpression significantly reduced the 
sensitivity of frataxin-deficient β-cells to brefeldin (Fig. 2G). Thus, mitochondrial 
oxidative stress is a key mechanism for β-cell apoptosis in FRDA.  
 
Frataxin-deficiency activates the intrinsic pathway of apoptosis in β-cells.  
Mitochondrial cytochrome c release is a hallmark of activation of the intrinsic 
pathway of apoptosis. Frataxin silencing induced cytochrome c release in control 
condition and after oleate treatment (Fig. 3A-B). Treatment with the ROS scavenger 
MnTMPyP prevented cytochrome c release (Fig. 4), showing that oxidative stress 
contributes to the activation of the intrinsic pathway of apoptosis under frataxin 
deficiency. We next examined the pro- and anti-apoptotic proteins of the Bcl-2 family 
controlling this apoptosis pathway (20, 21, 35, 36). Frataxin silencing in β-cells 
induced the mRNA expression of the pro-apoptotic BH3-only sensitizer DP5, as well 
as the BH3-only activators Bim and Puma (Fig. 3C). At the protein level, frataxin 
deficiency induced the Bim isoforms BimL and BimS, the latter being the most pro-
apoptotic Bim splice variant (37) (Fig. 3D-E and Supplementary Material, Fig. S2A-
B). For DP5 and Puma there are no good antibodies available. Frataxin silencing also 
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activated the BH3-only sensitizer Bad by dephosphorylation (Fig. 3D-E). Frataxin 
deficiency did not impair the expression of the anti-apoptotic proteins Bcl-XL or Bcl-2 
in control condition or after oleate treatment (Supplementary Material, Fig. S2C-E). 
Instead, Bcl-XL protein expression was induced after frataxin silencing 
(Supplementary Material, Fig. S2C-D), possibly as a protective mechanism to prevent 
β-cell demise. Taken together, these results indicate that frataxin deficiency leads to 
upregulation or activation of pro-apoptotic Bcl-2 proteins but not to downregulation 
of pro-survival ones.  
 
The pro-apoptotic Bcl-2 proteins Bad, DP5 and Bim mediate apoptosis in 
frataxin-deficient β-cells. 
We next examined whether Bad, DP5, Bim or Puma mediate cell death in frataxin-
deficient cells. To this end, we silenced frataxin in clonal β-cells, alone or combined 
with Bad, DP5, Bim or Puma siRNAs, achieving more than 50% knockdown 
(Supplementary Material, Fig. S3). Bad knockdown reduced β-cell apoptosis in 
control condition and after oleate or brefeldin exposure (Fig. 5A-B). DP5 silencing 
prevented oleate- but not brefeldin-induced apoptosis (Fig. 5D-E), while Bim 
knockdown was protective against both (Fig. 5G-H). Bad, DP5 and Bim silencing 
also prevented oleate-induced apoptosis in frataxin-deficient primary rat β-cells (Fig. 
5C, F, I). Puma knockdown was not protective for frataxin-deficient β-cells (Fig. 5J-
K). The results were confirmed by Western blots for the effector caspase-3, that was 
significantly less activated following Bad, DP5 and Bim silencing but not after Puma 
knockdown (Supplementary Material, Fig. S4).  
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The intrinsic pathway of apoptosis is activated in iPSC-derived neurons 
from FRDA patients.  
To evaluate if frataxin deficiency in neurons also leads to activation of the intrinsic 
pathway of apoptosis we differentiated fibroblast-derived iPSCs from two FRDA 
patients and one age-matched healthy individual into neurons. Since heterogeneous 
responses between clones have been reported (25), two clones were examined per 
individual. As described by Hick and co-workers (25), fibroblasts from FRDA 
patients (FA1 and FA2) had expanded GAA repeats (800/600 and 900/400, 
respectively), whereas the control fibroblasts (CT) had normal GAA repeats (<20). 
The number of repeats was unstable during reprogramming, but stabilized in iPSC 
clones and during differentiation. Both FRDA iPSCs clones retained pathological 
GAA repeat expansions, ranging between 400 and 1000 triplets, with frataxin levels 
reduced at all stages to 20-30% of that of control cells (25). The neuronal phenotype 
of iPSC-derived neurons was confirmed by morphology, expression of specific 
neuronal markers such as β-III-tubulin and microtubule-associated protein 2 (MAP2), 
and their ability to generate sodium currents, action potentials and calcium transients 
(25). FRDA iPSC-derived neurons were shown to have impaired mitochondrial 
membrane potential and delayed functional maturation (25). We confirmed that 
differentiated neurons from both FRDA patients showed significantly reduced 
frataxin protein levels as compared to control cells (Fig. 6A and E). These FRDA 
neurons showed significantly enhanced cleavage of the initiator caspase-9 and the 
effector caspase-3 (Fig. 6A-C), demonstrating that the intrinsic pathway of apoptosis 
is activated. In keeping with the observations in β-cells, BimL and BimS expression 
was increased (Fig. 6D). In one of the four patient clones (FA 1A) caspase activation 
and Bim induction were not observed, in keeping with reported inter-clonal variation 
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(25). Taken together, these results point to activation of the intrinsic pathway of 
apoptosis in neurons through Bim induction as occurs in β-cells. 
 
Forskolin reduces mitochondrial oxidative stress and prevents activation 
of the intrinsic pathway of apoptosis in frataxin-deficient β-cells and iPSC-
derived neurons from FRDA patients.  
We have previously demonstrated that analogs of the incretins glucagon-like peptide-
1 (GLP-1) and glucose-dependent inhibitory peptide (GIP) are protective for frataxin-
deficient β-cells (10). The adenylyl cyclase stimulator forskolin reproduces this effect 
(10). We examined whether forskolin modifies mitochondrial oxidative stress in 
frataxin deficient--cells using the H2O2 fluorescent sensor HyperMito and the redox-
sensitive fluorescent probe mt-roGFP1. Forskolin treatment reduced mitochondrial 
H2O2 production and restored the mitochondrial redox state of frataxin-silenced cells 
(Fig. 7A-B). Forskolin fully protected frataxin-deficient β-cells from apoptosis under 
control condition and after brefeldin exposure, as determined by caspase-3 activation 
(Fig. 7C-D). This was paralleled by complete restoration of Bad phosphorylation (Fig. 
7C, E) and inhibition of Bim induction (Fig. 7F). Forskolin treatment also protected 
frataxin-deficient rat islet cells from brefeldin-induced apoptosis (Fig. 7G) and 
significantly reduced Bim induction (Fig. 7H and Supplementary Material, Fig. S5). 
Thus, cAMP induction protects frataxin deficient β-cells by reducing oxidative stress 
and preventing activation of the intrinsic pathway of apoptosis. We have previously 
shown that the GLP-1 analog exendin-4 and the GIP mimetic [D-Ala2]-GIP protect 
clonal β-cells from metabolic and ER stress-induced apoptosis (10). Exendin-4 
partially prevented brefeldin-induced apoptosis in frataxin-silenced rat islet cells 
(Supplementary Material, Fig. S6A). [D-Ala2]-GIP and forskolin protected frataxin-
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deficient human islet cells from oleate (Supplementary Material, Fig. S6B). These 
data show that incretin analogs are also protective in frataxin-deficient primary rat 
and human islets. To examine if enhanced cAMP formation is also protective in 
neurons from FRDA patients, iPSC-derived neurons from two FRDA patients were 
treated with forskolin (Fig. 7I-L). Forskolin treatment tended to reduce caspase-3 
activation in individual clones (Fig. 7I) and when pooling all samples (Fig. 7J). 
Expression of BimL and BimS was significantly reduced by forskolin in an individual 
clone (Fig. 7K) and in the pooled samples (Fig. 7L). These data suggest that cAMP 
inducers also prevent the activation of the intrinsic pathway of apoptosis in neurons 
from FRDA patients.  
 
Discussion 
FRDA is a neurodegenerative disease caused by decreased frataxin expression. The 
main cell types affected by frataxin deficiency are neurons from the dorsal root 
ganglia and dentate nucleus of the cerebellum, cardiomyocytes and pancreatic β-cells 
(3, 10, 38). Frataxin deficiency leads to β-cell dysfunction and death (10). Reduced 
mitochondrial membrane potential, decreased ATP production and insulin secretion 
contribute to the functional β-cell defect (10). Here, we show that frataxin deficiency 
in β-cells induces mitochondrial oxidative stress and activates the intrinsic pathway of 
apoptosis. Similar to observations in other cellular models of FRDA using RNA 
interference or frataxin knockout mouse cells (17, 39, 40), frataxin silencing in β-cells 
enhanced mitochondrial SOD2 expression, mitochondrial hydrogen peroxide 
production, hydroxyl radical formation and increased mitochondrial GSH oxidation 
(Fig. 1). This is probably the consequence of respiratory chain dysfunction. 
Respiratory chain complexes I, II, and III need Fe-S clusters as cofactors for proper 
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function. Reduced Fe-S cluster formation, as a consequence of frataxin deficiency, 
leads to impaired electron flow and premature electron leakage from the respiratory 
chain. These electrons react with molecular oxygen to form superoxide, which will in 
turn generate hydrogen peroxide via SOD2. In the presence of iron, hydrogen 
peroxide is transformed in the highly toxic hydroxyl radical via the Fenton reaction 
(41), leading to cell damage and death. Our data demonstrate that oxidative stress 
causes β-cell demise since chemical and genetic approaches to scavenge ROS protect 
frataxin-deficient cells from apoptosis (Fig. 2). Cell death in frataxin deficiency 
occurs through the intrinsic pathway of apoptosis (Fig. 3), and could be prevented by 
ROS scavenging (Fig. 4). The pro-apoptotic Bcl-2 family members Bad, DP5 and 
Bim are the key mediators of the intrinsic pathway of apoptosis (Fig. 5). Palomo and 
colleagues (17) previously suggested that shRNA-mediated frataxin silencing in 
neuron-like cells induces p53-mediated upregulation of Puma and Bax and caspase-3 
activation. We confirmed that frataxin silencing in β-cells induces Puma expression, 
but silencing this BH3-only activator was not cytoprotective suggesting that the p53-
Puma pathway does not play a role in apoptosis in frataxin deficient β-cells. 
Importantly, we demonstrate here that the intrinsic pathway of apoptosis is also 
activated in iPSC-derived neurons from FRDA patients and thus identify a common 
mechanism of cell death in two key cell types in FRDA (Fig. 6). Patient iPSC-derived 
cells are an invaluable in vitro model to gain pathogenic insight and test the impact of 
novel therapies. The differentiation of iPSCs into β-cells remains challenging, with 
current protocols requiring transplantation into mice in order to achieve in vivo β-cell 
maturation (42). 
After the identification of oxidative stress as a potential major contributor to FRDA 
pathology, a variety of antioxidants and stimulants of mitochondrial function were 
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considered as possible therapeutics. Coenzyme Q derivatives, such as idebenone, 
known for their ability to participate in the electron transport chain and their 
antioxidant properties, were tested in preclinical and clinical studies, but they did not 
demonstrate efficacy in modifying disease progression (43). Oxidative damage is also 
strongly implicated in the pathogenesis of other neurodegenerative diseases such as 
Huntington’s disease, amyotrophic lateral sclerosis, Alzheimer’s disease, stroke, and 
Parkinson’s disease. Clinical trials using anti-oxidant molecules such as vitamin E 
and C and coenzyme Q derivatives also failed to demonstrate efficacy to prevent or 
treat oxidative stress damage in those diseases (44, 45). It has been proposed that 
cAMP/PKA signaling modulates redox homeostasis in -cells (46). Here we 
demonstrate that forskolin treatment normalizes mitochondrial oxidative status and 
prevents activation of the intrinsic pathway of apoptosis in frataxin-silenced β-cells 
and primary islets (Fig. 7). The incretin analogs exendin-4 and [D-Ala2]-GIP were 
also protective in frataxin-deficient rat and human islets. It is of great interest that 
forskolin also tended to protect FRDA patients’ iPSC-derived neurons from apoptosis 
(Fig. 7). In frataxin-deficient cells the forskolin- and incretin-mediated protective 
effect may be the consequence of reduced oxidative stress, but additional cAMP-
mediated ROS-independent protective mechanisms may also play a role. We did not 
evaluate the impact of forskolin treatment on mitochondrial function of frataxin-
deficient cells, but it is conceivable that the normalization of mitochondrial oxidative 
status decreases mitochondrial damage and improves mitochondrial function. 
Taken together our results suggest that cAMP induction by incretin analogs may have 
therapeutic potential to prevent β-cell and neuronal cell loss in FRDA. GIP and GLP-
1 receptors are expressed throughout the brain, and the GLP-1 analogs exendin-4 and 
liraglutide have been shown to cross the blood-brain-barrier (47). Their therapeutic 
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potential is being considered in amyotrophic lateral sclerosis (48), Alzheimer’s (49), 
Parkinson’s (50), and Huntington’s disease (51) and stroke (52, 53). This preclinical 
study identifies incretin analogs as a potential new treatment for FRDA, where they 
may be useful to prevent/delay neurodegeneration and diabetes. 
 
Materials and Methods 
Culture of INS-1E cells, primary rat β-cells, dispersed rat and human 
islets, and iPSC-derived neurons.  
Clonal rat INS-1E cells (a kind gift from Dr C. Wollheim, Centre Médical 
Universitaire, Geneva, Switzerland) were cultured in RPMI 1640 medium as 
previously described (54, 55). Rat islets were isolated by collagenase digestion from 
male Wistar rats (Charles River Laboratories) housed and used following the rules of 
the Belgian Regulations for Animal Care, and with approval of the local Ethical 
committee. Islets were hand-picked under the stereomicroscope and dispersed. β-cells 
were purified from the dispersed rat islets by autofluorescence-activated cell sorting 
(FACSAria; BD Bioscience) and cultured as described (56). Human islets from non-
diabetic organ donors (n=5, age 53±3 years, BMI 26±2 kg/m2) were isolated by 
collagenase digestion and density gradient purification (57) in Pisa, Italy. The islets 
were cultured, dispersed and transfected as previously described (58). The mean 
percentage of β-cells of the human islet preparations was 53±6%, as determined by 
insulin immunofluorescence (59). For neuronal differentiation, iPSCs from two 
FRDA patients and one age-matched unrelated control individual were treated for 14 
days with 500 ng/ml of Noggin (60). To allow the formation of neurospheres, the 
cells were then cultured in NBN media (neurobasal media A+B27+N2) supplemented 
with FGF-2 and EGF (both 20 ng/ml; Peprotech, UK). Neuronal precursors were 
 at Bibliotheques de l'U
CL on January 6, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
15	
 
maintained and propagated as neurospheres as previously described (25). For 
neuronal differentiation, neurospheres were plated on laminin-coated glass coverslips 
in NBN media (without proliferating factors) containing brain-derived neurotrophic 
factor (BDNF) and neurotrophin 3 (NT3) (100 ng/ml; Peprotech). Medium was 
replaced every 2-3 days. These cells have been characterized in detail by Hick et al 
(25). Differentiated neurons were collected after 2, 5 or 7 weeks differentiation.   
 
Cell treatment and apoptosis assays.  
INS-1E cells were exposed to 0.5 mM oleate in RPMI 1640 medium containing 1% 
fetal bovine serum (FBS) and 0.75% FFA-free bovine serum albumin (BSA) (10). 
Primary β-cells and dispersed rat and human islet cells were exposed to 0.5 mM 
oleate in Ham’s F-10 medium without serum and 1% charcoal-absorbed BSA (10, 
61). The oleate stock solution (50 mM) was prepared by dissolving oleate (sodium 
salt, Sigma) in 90% ethanol (10, 62, 63). The chemical ER stressor brefeldin-A (an 
inhibitor of ER-to-Golgi vesicle transport) was used at a concentration of 0.1 g/ml 
(10). The cell-permeable superoxide dismutase (SOD)/catalase mimetic (31-33) 
manganese (III) tetrakis(1-methyl-4-pyridyl) porphyrin pentachloride (MnTMPyP, 
Alexis Biochemicals) was used at a concentration of 25 μM, 4,5-dihydroxybenzene-
1,3-disulfonate (Tiron, Sigma-Aldrich) at a concentration of 12.5 μM, the adenylyl 
cyclase stimulator forskolin at a concentration of 20 μM,, the GLP-1 analog exendin-
4 and the GIP mimetic [D-Ala2]-GIP at concentrations of 50 nM and 100 nM, 
respectively (10). In all treatments the control condition contained a similar 
concentration of the vehicle (ethanol, DMSO or PBS).  
Apoptosis was determined by fluorescence microscopy after Hoechst 33342 (5 g/ml; 
Sigma-Aldrich) and propidium iodide (5 g/ml) staining (10), Western blotting for 
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cleaved caspase-3 (10, 61), and apoTox-Glo Triplex Assay (Promega) according to 
the manufacturer’s instructions.  
 
Analysis of H2O2 levels using HyPer vectors.  
The pHyPerMito and pHyPerCyto eukaryotic expression vectors (Evrogen, Moscow, 
Russia) were used for mitochondrial and cytoplasmic expression of the fluorescent 
H2O2 sensor protein HyPer, as previously described (64). Stable clones of INS-1E 
cells expressing these vectors (INS-1E-HyPerMito and INS-1E-HyPerCyto), verified 
by fluorescence measurements, were transfected with a siRNA targeting rat frataxin 
(siFx). 48h after transfection the cells were treated or not for 24h with oleate or 
brefeldin. Mitochondrial or cytosolic H2O2 production was detected as HyPer 
oxidation, measured by fluorescence (475/427 nm excitation and 520 nm emission) in 
a Victor2 1420 Multilabel Counter fluorescence reader (Perkin Elmer). The data were 
expressed as mean values of the F475/F427 ratio. 
 
Estimation of hydroxyl radical formation. 
Hydroxyl radical formation was estimated using the fluorescent dye 3'-(p-
hydroxyphenyl) fluorescein (HPF) (Life Technologies) according to the 
manufacturer's instructions. 
 
Mitochondrial glutathione redox state measurement. 
The mitochondrial glutathione redox state was analyzed using the redox-sensitive 
fluorescent probe roGFP1 targeted to the mitochondria (mt-roGFP1). INS-1E cells 
were plated in glass coverslips and transfected with control or frataxin siRNA. 16h 
after transfection the cells were treated or not for 24h with 20 μM forskolin, and then 
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they were infected with an adenovirus encoding mt-roGFP1 under the control of the 
cytomegalovirus promoter (multiplicity of infection 25–50). After infection the cells 
were further cultured for 48h in the presence or absence of 20 μM forskolin. After 
culture, the coverslips were mounted at the bottom of a 37°C temperature-controlled 
chamber placed on the stage of an inverted microscope equipped with a 40x objective. 
Cells were perifused with bicarbonate-buffered Krebs solution containing 10 mM 
glucose at a flow rate of 1 ml/min. Cell fluorescence ratio (λexitation400/480 nm / 
λemission535 nm) was measured every 30s. After 20 min of perifusion, the cells were 
perifused with 10 M dithiothreitol (DTT) to maximally reduce roGFP1 (set to 0%), 
followed by 100 μM aldrithiol to maximally oxidize it (set to 100%). The 
fluorescence ratio was expressed in percentage of the maximally reduced and the 
maximally oxidized forms of roGFP1 (normalized fluorescence ratio). 
 
Catalase activity measurement.  
Frataxin was knocked down by siRNA (see below) in control INS-1E cells or INS-1E 
cells stably overexpressing catalase inside the mitochondria. Catalase enzyme activity 
was measured by ultraviolet spectroscopy in control and catalase overexpressing cell 
lysates. The decomposition of H2O2 was monitored at 240 nm as previously described 
(65). One unit of catalase activity was defined as 1 μM of H2O2 per minute at 25°C.  
 
RNA interference.  
INS-1E cells, FACS-purified primary rat -cells, and dispersed rat and human islet 
cells were transfected overnight with 30 nM control siRNA (Qiagen) or siRNAs 
targeting rat or human frataxin, rat DP5, Bim, Puma or Bad (all from Invitrogen), 
using Lipofectamine RNAiMAX (Invitrogen). The siRNAs targeting frataxin (10), 
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DP5 (66), Puma (67), Bim (68) and Bad (69) have been previously validated in β-
cells. siRNA-lipid complexes were formed in Opti-MEM (Invitrogen) for 20 min as 
previously described (10). siRNA sequences and Lipofectamine concentrations are 
described in Supplementary Material, Tables S1 and S2. 
  
 Immunofluorescence. 
Cytochrome c release was examined by immunofluorescence (66, 67). INS-1E cells 
plated on poly-lysine coated coverslips were transfected with control or frataxin 
siRNA. 16h after transfection cells were cultured for 48h in the presence of 25 μM 
MnTMPyP and then treated for 24h with oleate alone or combined with MnTMPyP. 
The cells were fixed with 4% formaldehyde (70), permeabilized with 0.1% Triton X-
100, blocked with 3% FBS and incubated overnight at 4°C with mouse anti-
cytochrome c (1:500, BD Biosciences). Alexa Fluor 488 goat anti-mouse IgG (H+L) 
(1:500, Molecular Probes, Invitrogen) was used as secondary antibody. Nuclei were 
stained with Hoechst 33342 and the slides analyzed by inverted fluorescence 
microscopy (Zeiss Axiovert 200, Oberkochen, Germany).  
 
mRNA extraction and real-time PCR.  
mRNA was isolated from INS-1E cells, primary rat β-cells and dispersed rat islet cells 
using the Dynabeads mRNA DIRECT kit (Invitrogen) and reverse transcribed as 
previously described (63, 71). Real-time PCR was performed using Rotor-Gene SyBR 
Green on a Rotor-Gene Q cycler (Qiagen) (72), or using Q SYBR Green Supermix 
(BIO-RAD) on a MyiQ2 instrument Single Color (BIO-RAD) (59, 63). Gene 
expression was calculated as copies/ml using the standard curve approach (73). 
Standards were prepared in conventional PCR. Expression values were corrected for 
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the expression of the reference gene GAPDH that was not modified by the 
experimental conditions. The primer sequences are provided in Supplementary 
Material, Tables S3 and S4. 
 
Western blotting.  
INS-1E cells, dispersed rat islet cells or iPSC-derived neurons were lysed in Laemmli 
buffer. Total extracts were resolved in 10-15% SDS-Page and transferred to 
nitrocellulose membrane. Immunoblotting was performed using antibodies against 
frataxin (Santa Cruz), cleaved caspase-3 (Cell Signaling), cleaved caspase-9 (Cell 
Signaling), α-tubulin (Sigma-Aldrich), total Bim (Cell Signaling), human P-Bad 
(Ser112, Cell Signaling), total Bad (Cell Signaling), Bcl-XL (Cell Signaling), and Bcl-
2 (Cell Signaling). Protein detection was done using horseradish peroxidase-
conjugated secondary antibodies and SuperSignal West Femto chemiluminescence 
revealing reagent (Thermo Scientific). Immunoreactive bands were detected with a 
ChemiDoc XRS+ system and Image Lab software (BIO-RAD) (10). Protein levels 
were corrected for levels of -tubulin. 
 
Statistical analysis.  
Data are shown as means ± SE. Non-normally distributed variables were log-
transformed before statistical testing. Comparisons between groups were made by 
ANOVA followed by two-sided Student’s paired t test with Bonferroni correction for 
multiple comparisons. Comparisons between iPSC-derived neurons from control and 
FRDA patients were made by unpaired t test. A p value <0.05 was considered 
statistically significant. 
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Legends to Figures 
Figure 1. Frataxin deficiency induces mitochondrial oxidative stress in β-cells. 
INS-1E cells were transfected with control siRNA (siCT) or siRNA targeting rat 
frataxin (siFx). Frataxin and SOD2 mRNA expression was measured by real-time 
PCR and expressed as fold of siCT (A and D). Frataxin protein expression was 
examined by Western blot and normalized to the expression of -tubulin (B). 
Apoptosis was evaluated by Hoechst 33342/propidium iodide staining (C). (E and F) 
INS-1E cells were transfected with siCT or siFx together with the expression vector 
HyPerMito or HyPerCyto, coding for the fluorescent H2O2 sensor protein HyPer 
targeted to the mitochondria or the cytosol, respectively. 48h after transfection the 
cells were treated or not (CT) for 24h with oleate (OL, 0.5 mM) or brefeldin (BR, 0.1 
g/ml). HyPer oxidation, measured by fluorescence count reader (F475/F427), was 
used as indicative of mitochondrial or cytosolic H2O2 production. Hydroxyl radical 
formation, estimated by fluorescent HPF, was examined in frataxin expressing (siCT) 
of frataxin deficient (siFx) INS-1E cells treated or not with OL or BR for 24h (G). 
Mitochondrial glutathione redox state was analyzed using the redox-sensitive 
fluorescent probe roGFP1 targeted to the mitochondria (mt-roGFP1). Frataxin 
deficient (siFx) or frataxin competent (siCT) in INS-1E cells were infected with an 
adenovirus encoding mt-roGFP1. 48h after infection the cells were perifused with 
buffered Krebs solution containing 10 mM glucose and mitochondrial glutathione 
redox state was assessed by measuring the mt-roGFP1 fluorescence ratio (λex400/480 
nm/λem535 nm). The results were normalized to the maximally reduced and 
maximally oxidized mt-roGFP1 fluorescence ratio following cell perifusion with DTT 
and aldrithiol, respectively (H). Results are means ± SE of 3-8 independent 
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experiments. * Treated vs CT, *p<0.05, ** p<0.01, *** p<0.001; § siFx vs siCT, § 
p<0.05, §§ p<0.01, by paired t test. 
 
Figure 2. ROS scavenging partially prevents apoptosis in frataxin-deficient β-
cells. INS-1E cells or dispersed rat islet cells were transfected with control siRNA 
(siCT) or siRNA targeting frataxin (siFx). 16h after transfection the cells were 
exposed or not for 48h to the ROS scavengers MnTMPyP (25 M), or 4,5-
dihydroxybenzene-1,3-disulfonate (Tiron, 12.5 M) and then treated or not (CT) for 
24h with oleate (OL, 0.5 mM), or brefeldin (BR, 0.1 g/ml), alone or combined with 
MnTMPyP or Tiron. Apoptosis was examined by Hoechst 33342/propidium iodide 
staining (A, D, F, INS-1E cells; E, dispersed rat islet cells), or Western blots for 
cleaved caspase-3 (B), quantified by densitometry and normalized to α-tubulin (C). 
(G) Frataxin was silenced in wild type or mitochondrial catalase-overexpressing INS-
1E cells (Mito Cat). Cells were then treated for 24h with brefeldin (BR). Caspase-3 
activation was measured using the ApoTox kit. Results are means ± SE of 3-5 
independent experiments. * Treated vs CT, *p<0.05, ** p<0.01, *** p<0.001; § siFx 
vs siCT, § p<0.05, §§ p<0.01, §§§ p<0.001; # presence vs absence of MnTMPyP or 
wild type vs Mito Cat INS-1E cells, # p<0.05, by paired ratio t test. 
 
Figure 3. Frataxin deficiency activates the intrinsic pathway of apoptosis in β-
cells. INS-1E cells were transfected with control siRNA (siCT) or siRNA targeting 
frataxin (siFx). 48h after transfection the cells were treated or not (CT) with oleate 
(OL, 0.5 mM) for 24h. Cytochrome c release was evaluated by immunofluorescence. 
Representative pictures are shown in (A). Arrows indicate cells with diffuse 
cytoplasmic staining for cytochrome c. (B) Quantification of A (n=4-5). More than 
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900 cells were counted in each experiment. (C-E) DP5, Bim and Puma expression, 
caspase-3 activation and BAD phosphorylation were examined 72h after frataxin 
knockdown. DP5, Puma and Bim mRNA expression was measured by real-time PCR 
and corrected for the reference gene GAPDH (C). Caspase-3 activation, Bim protein 
expression and BAD phosphorylation were examined by Western blot (D). (E) 
Densitometry of D. Results are means ± SE of 3-9 independent experiments. * 
Treated vs CT, * p<0.05, ** p<0.01; § siFx vs siCT, § p<0.05, §§ p<0.01, by paired t 
test. 
 
Figure 4. Oxidative stress activates the intrinsic pathway of apoptosis in 
frataxin-deficient β-cells. Frataxin was silenced in INS-1E cells by siRNA (siFx). 
16h after transfection the cells were cultured in the absence (CT) or presence of 
MnTMPyP (25 mM) for 48h. The cells were then treated or not (CT) with oleate (OL, 
0.5 mM) alone or combined with MnTMPyP for 24h. Cytochrome c release was 
evaluated by immunofluorescence. (A) Representative pictures are shown. Arrows 
indicate cells with diffuse cytoplasmic cytochrome c staining. (B) Quantification of 
A. More than 900 cells were counted in each experiment. Results are means ± SE of 5 
independent experiments. * Treated vs CT, p<0.05; # presence vs absence of 
MnTMPyP; # p<0.05, ### p<0.001, by paired t test. 
 
Figure 5. BAD, DP5 and Bim but not Puma mediate apoptosis in frataxin-
deficient β-cells. Frataxin was silenced (siFx) or not (siCT) in INS-1E cells (A, B, D, 
E, G, H, J, K) and primary rat β-cells (C, F, I) alone or combined with BAD (A-C), 
DP5 (D-F), Bim (G-I) or Puma siRNA (J-K). Cells were then treated or not (CT) for 
24h with oleate (OL, 0.5 mM) or brefeldin (BR, 0.1 l/ml). Apoptosis was evaluated 
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by Hoechst 33342/propidium iodide staining. Results are means ± SE of 3-4 
independent experiments. * Treated vs CT, * p<0.05, ** p<0.01; § siFx vs siCT, 
§p<0.05, §§ p<0.01; # siFx vs double knockdown, # p<0.05, ## p<0.01, ### p<0.001, 
by paired t test or ANOVA followed by paired t test with Bonferroni correction for 
multiple comparisons.  
 
Figure 6. The intrinsic pathway of apoptosis is activated in iPSC-derived 
neurons from FRDA patients. Caspase-3 and -9 activation, Bim and frataxin 
expression were examined by Western blot (A) in iPSC-derived neurons (2 and 5 
weeks differentiation) from one healthy control (CT) and two FRDA patients (FA 1 
and 2), two clones of each (indicated as A and B). (Β-E) Densitometry of A. Symbols 
represent independent experiments. *FRDA vs CT, * p<0.05, ** p<0.01, *** 
p<0.001, by unpaired t test. 
 
Figure 7. Forskolin reduces oxidative stress and prevents activation of the 
intrinsic pathway of apoptosis in frataxin-deficient β-cells and iPSC-derived 
neurons from FRDA patients. Mitochondrial H2O2 production was measured using 
the H2O2 fluorescent sensor HyPer targeted to the mitochondria (HyPerMito). 
Frataxin was silenced (siFx) or not (siCT) in INS-1E cells together with the 
expression vector HyPerMito, 48h after transfection the cells were treated or not (CT) 
for 24h with 20 M forskolin (FK). HyPer oxidation, measured by fluorescence count 
reader (F475/F427), was used as indicative of mitochondrial H2O2 production. The 
results are means  SE of 7 independent experiments (A). Mitochondrial glutathione 
redox state was analyzed using the redox-sensitive fluorescent probe roGFP1 targeted 
to the mitochondria (mt-roGFP1). Frataxin was silenced or not in INS-1E cells. 16h 
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after transfection the cells were treated or not (CT) for 24h with 20 M forskolin 
(FK), and then infected with an adenovirus encoding mt-roGFP1. After infection, the 
cells were further treated or not with forskolin for 48h. The cells were then perifused 
with buffered Krebs solution containing 10 mM glucose and mitochondrial 
glutathione redox state was assessed by measuring the mt-roGFP1 fluorescence ratio 
(λex400/480 nm/λem535 nm). The results (means  SE of 3 independent experiments) 
were normalized to the maximally reduced and maximally oxidized mt-roGFP1 
fluorescence ratio following cell perifusion with DTT and aldrithiol, respectively (B). 
INS-1E (C-F) and dispersed rat islet cells (G-H) were transfected with siCT or siFx 
and 48h later treated or not (CT) for 24h with brefeldin (BR, 0.1 l/ml) alone or 
combined with forskolin (FK, 20 M). Western blots for caspase-3 activation and Bad 
phosphorylation were used to assess apoptosis in INS-1E cells. (C) Representative 
blot and (D-E) densitometry of the Western blots (n=4 independent experiments). P-
Bad was normalized to total Bad and cleaved caspase-3 to α-tubulin. In dispersed rat 
islet cells apoptosis was examined by Hoechst 33342/propidium iodide staining (G). 
Bim mRNA expression in INS-1E cells (F) and dispersed islets (H) was measured by 
real-time PCR and corrected for the reference gene GAPDH. Results are means ± SE 
of 3-4 independent experiments. iPSC-derived neurons from two FRDA patients (FA 
1 and 2), two clones of each (indicated as A and B) (5 and 7 weeks differentiation), 
were cultured for 72h in the absence (CT) or presence of 20 M forskolin (FK). 
Densitometry of the Western blots for caspase-3 cleavage (I-J) and BimL + BimS 
expression (K-L). Symbols represent independent experiments. All observations for 
the 4 clones were pooled in panels J and L. * Treated vs CT, * p<0.05, ** p<0.01; § 
siFx vs siCT, § p<0.05, §§§ p<0.001; # with FK vs without FK, # p<0.05, ## p<0.01, 
by ratio t test. 
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Abbreviations: DTT, dithiothreitol; ER, endoplasmic reticulum; FFA, free fatty acid; 
FRDA, Friedreich’s ataxia; GIP, glucose-dependent inhibitory peptide; GLP-1, 
glucagon-like peptide-1; GSH, reduced glutathione; iPSC, induced pluripotent stem 
cell; ROS, reactive oxygen species; SOD, superoxide dismutase. 
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